Skip to content

Comparison of the effectiveness of secretome combined with microneedling in patients with skin aging

Comparison of the effectiveness of secretome extracted from peripheral adipose tissue combined with microneedling in patients with skin aging

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
IRCT
Registry ID
IRCT20140705018373N9
Enrollment
20
Registered
2025-07-10
Start date
2025-06-22
Completion date
Unknown
Last updated
2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Facial Wrinkles. Changes in skin texture

Interventions

Intervention 1: Intervention group: In this group, one side of the participants' face (based on randomization) was treated with microneedling with secretome extracted from placental mesenchymal stem c

Sponsors

Tabriz University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
30 Years to 59 Years

Inclusion criteria

Inclusion criteria: Women aged 30-59 Have not had facial Botox injections within 6 months prior to study entry Have not had facial filler injections within 1 year prior to study entry Have evidence of skin aging including superficial wrinkles

Exclusion criteria

Exclusion criteria: Patients with severe dermatitis or psoriasis or any other Koebner-positive disease. Acne, herpes, or autoimmune diseases History of cancer or chemotherapy Pregnancy or breastfeeding Taking certain medications, including corticosteroids or immunosuppressants Presence of coagulation problems Evidence of keloids or scars or difficulty in wound healing

Design outcomes

Primary

MeasureTime frame
Severity of skin wrinkles. Timepoint: Before the intervention, four weeks after the first session, eight weeks after the first session, and twelve weeks after the first session. Method of measurement: Visual analog scale and clinical assessment.;Patient satisfaction. Timepoint: Before the intervention began, four weeks after the first session, eight weeks after the first session, and twelve weeks after the first session. Method of measurement: Visual analog scale.;Treatment side effects. Timepoint: Before the intervention began, four weeks after the first session, eight weeks after the first session, and twelve weeks after the first session. Method of measurement: Clinical assessment.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohamad Reza Ranjkesh

Tabriz University of Medical Sciences

ranjkeshm@tbzmed.ac.ir+98 914 116 5061

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026